RT Journal Article
SR Electronic
T1 50-valent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 053967
DO 10.1101/053967
A1 Sujin Lee
A1 Minh Trang Nguyen
A1 Michael G. Currier
A1 Joe B. Jenkins
A1 Elizabeth A. Strobert
A1 Adriana E. Kajon
A1 Ranjna Madan-Lala
A1 Yury A. Bochkov
A1 James E. Gern
A1 Krishnendu Roy
A1 Xiaoyan Lu
A1 Dean D. Erdman
A1 Paul Spearman
A1 Martin L. Moore
YR 2016
UL http://biorxiv.org/content/early/2016/05/17/053967.abstract
AB As the predominant etiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. We approached this problem straightforwardly. We tested the hypothesis that increasing virus input titers in polyvalent inactivated HRV vaccine will result in broad nAb responses. Here, we show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. We for the first time generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.